September 20, 2026

Chemotherapy and Targeted Therapy

The Paradox of Progress: Why Pharmaceutical Sustainability Goals Are Struggling Against Rising Emissions the-paradox-of-progress-why-pharmaceutical-sustainability-goals-are-struggling-against-rising-emissions

The Paradox of Progress: Why Pharmaceutical Sustainability Goals Are Struggling Against Rising Emissions

Neng Nana June 15, 2026
The global healthcare sector, long viewed as a bastion of wellness and life-saving innovation, is confronting an...
Read More Read more about The Paradox of Progress: Why Pharmaceutical Sustainability Goals Are Struggling Against Rising Emissions
Bridging the Gap: How Novel Immune Therapies Are Reshaping the Treatment of TBI and Alzheimer’s Disease bridging-the-gap-how-novel-immune-therapies-are-reshaping-the-treatment-of-tbi-and-alzheimers-disease

Bridging the Gap: How Novel Immune Therapies Are Reshaping the Treatment of TBI and Alzheimer’s Disease

Azzam Bilal Chamdy June 15, 2026
Traumatic brain injury (TBI) is not merely a singular event—it is a chronic, often progressive condition that...
Read More Read more about Bridging the Gap: How Novel Immune Therapies Are Reshaping the Treatment of TBI and Alzheimer’s Disease
Biopharma Industry Update: AstraZeneca’s GLP-1 Ambitions and Strategic Shifts Across the Sector biopharma-industry-update-astrazenecas-glp-1-ambitions-and-strategic-shifts-across-the-sector

Biopharma Industry Update: AstraZeneca’s GLP-1 Ambitions and Strategic Shifts Across the Sector

Raul Delapena Setiawan June 15, 2026
The global biopharmaceutical landscape continues to undergo rapid transformation, characterized by aggressive pursuits in metabolic health, cutting-edge...
Read More Read more about Biopharma Industry Update: AstraZeneca’s GLP-1 Ambitions and Strategic Shifts Across the Sector
Beyond the Burn: Rubedo Life Sciences Challenges the Status Quo of Actinic Keratosis Treatment beyond-the-burn-rubedo-life-sciences-challenges-the-status-quo-of-actinic-keratosis-treatment

Beyond the Burn: Rubedo Life Sciences Challenges the Status Quo of Actinic Keratosis Treatment

Nana Wu June 14, 2026
For millions of individuals, the diagnosis of actinic keratoses (AK)—rough, scaly, sun-damaged skin patches—marks the beginning of...
Read More Read more about Beyond the Burn: Rubedo Life Sciences Challenges the Status Quo of Actinic Keratosis Treatment
Ethyreal Bio Emerges from Stealth with $101 Million to Tackle Graves’ Disease and Thyroid Eye Disease ethyreal-bio-emerges-from-stealth-with-101-million-to-tackle-graves-disease-and-thyroid-eye-disease

Ethyreal Bio Emerges from Stealth with $101 Million to Tackle Graves’ Disease and Thyroid Eye Disease

Nana Wu June 14, 2026
By Delilah Alvarado Published June 10, 2026 In a significant move that could reshape the treatment landscape...
Read More Read more about Ethyreal Bio Emerges from Stealth with $101 Million to Tackle Graves’ Disease and Thyroid Eye Disease

You may have missed

mastering-the-gravity-defying-flow-the-art-of-the-ashtanga-jump-back

Mastering the Gravity-Defying Flow: The Art of the Ashtanga Jump-Back

Ammar Sabilarrohman September 20, 2026
cultivating-prosperity-the-bridges-engine-and-the-future-of-rural-agriculture-1

Cultivating Prosperity: The BRIDGES Engine and the Future of Rural Agriculture

Basiran September 20, 2026
a-lifesaving-breakthrough-for-brca-carriers-cambridge-study-confirms-bilateral-salpingo-oophorectomy-significantly-reduces-early-death-risk

A Lifesaving Breakthrough for BRCA Carriers: Cambridge Study Confirms Bilateral Salpingo-Oophorectomy Significantly Reduces Early Death Risk

Laily UPN September 20, 2026
the-pan-viral-frontier-can-cocrystal-pharma-rewrite-the-rules-of-antiviral-development-1

The Pan-Viral Frontier: Can Cocrystal Pharma Rewrite the Rules of Antiviral Development?

Rifan Muazin September 20, 2026